The meeting invited residents to share their flooding experiences over the past few years. The study hopes to offer potential ...

Study objective Stillbirth is burdensome in low-income and middle-income countries (LMICs), especially in sub-Saharan Africa ...

SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

The book traces violations of freedom of religion and belief since 2014, extensively documenting communal violence, hate ...

How should we approach the study of history? An unfortunate trend has been to implement “history by theory” in which ...

Follow-up studies published in 1992, 2004, 2012 and 2022 corroborated trends, though details differed. Some specific ...

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...

Self-driving vehicles are also set to see a number of advancements going forward. Self-driving cars are classified into six ...

Leap Therapeutics, Inc. (NASDAQ:LPTX) released significant updates regarding its recent clinical findings and corporate presentation. In a press release titled “Leap Therapeutics Reports Initial ...

The world's largest clinical research trial in hyperbaric medicine is taking place on the USF Campus right now, studying its impact on Traumatic Brain Injury.

SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025.